Pre-Conference Workshop Day

PRE-CONFERENCE WORKSHOP DAY - SEPTEMBER 21, 2021

Our workshops are streamed so you are able to attend 3 out of 6 workshops. You can choose A or B, followed by C or D, followed by E or F. Do you want to attend all of our workshops? Check out our group booking discounts so you can bring your colleagues!

Workshop A 9.00am EDT I 6.00am PDT

Degradation vs Inhibition – Benchmarking Therapeutic Modalities

This industry continues to progress from strength to strength, and G12C inhibition appears to pave the way for successful therapy against RAS driven cancer. Despite this, a huge amount of data demonstrates the viability of degradation as a powerful therapeutic modality against the RAS family of proteins. This session will consider the successes, challenges, and applications of each approach as we consider the potential of next-generation therapy reaching the patient.

In this session we will look at:

  • Fundamentals behind degradation and inhibition approaches
  • What are the limitations behind each approach?
  • Applications and considerations for both approaches a viable and effective therapy in the patient
Picture1

Darryl McConnell
Senior Vice President & Head Research Site Austria
Boehringer Ingelheim RCVar Pharmacology
NYU Grossman School of Medicine

Lim Shuhui_photo

Shuhui Lim
Senior Scientist

MSD

Workshop B 9.00am EDT I 6.00am PDT

Treating Patient Resistance in KRAS Therapies

Despite KRAS existing as one of the most common human oncogenes, resistance to anti-RAS drugs remains a critical issue preventing successful in-patient therapies. Through targeting RAS effector proteins, harnessing combination therapies and a comprehensive understanding of resistance mechanisms in patients, this session will open the floor to clinicians and academic experts to facilitate discussion into this crucial element of RAS drug development preventing clinical success.

In this session we will look at:

• Discussing the importance of investigating patterns and mechanisms of resistance induced in patients
• Discussing how modelled resistance translates to in-patient therapies and resistance seen in patients with KRAS mutant cancers
• Reviewing ongoing clinical trials and available data investigating and treating resistance in patients
• Exploring the bottlenecks of successfully treating resistance in RAS driven cancers

Sandra Misale, MSKCC

Sandra Misale
Research Associate
Memorial Sloan Kettering Cancer Center

Tetsuya Mitsodomi, Kindai University

Tetsuya Mitsudomi
Professor & Senior Staff
Kindai University Faculty of Medicine

Jurgen Moll, Sanofi

Jurgen Moll
Head of Molecular Oncology
Sanofi

Morning Break & Speed Networking 11.00 | 8.00

Workshop C 12.00pm EDT I 9.00am PDT

Intracellular Biologics as Enabling Tools for Advancing RAS Biology and Accelerating RAS Drug Discovery

Intracellular biologics, including antibodies, binding proteins and peptides, can be invaluable tools to advance mechanistic understanding of RAS biology and optimize drug discovery against RAS proteins. This approach can reveal novel vulnerabilities, identify effective inhibitors of RAS, and enable the discovery of viable anti-RAS therapies. This session will explore the fundamental methodologies of this approach and its potential uses to accelerate the field of RAS targeted therapies.

In this session we will look at:

  • Overview of adopting an intracellular biologics approach for drug discovery
  • How this approach can be applied specifically to RAS targets
  • How intracellular biologics identify novel functional and therapeutically exploitable surfaces on RAS
  • How these “tool biologics” can facilitate small molecule drug discovery for RAS
  • How converting these anti-RAS biologics to “biodegraders” could enable RAS degradation in isoform, allele, or nucleotide-occupancy selective manners
  • What are potential future applications of this approach beyond the RAS family of proteins?
Shohei Koide, NUY

Shohei Koide, Professor
Perlmutter Cancer Center at NYU Langone Health, and Department of Biochemistry and Molecular Pharmacology
NYU Grossman School of Medicine

Rachel Bond, SyntheX

Rachel Bond
Research Scientist
SyntheX

Workshop D 12.00pm EDT I 9.00am PDT

Biomarkers, Diagnostics & RAS Driven Cancers – The Importance of Mutation Detection for Optimizing Patient Outcome

There is a wealth of evidence demonstrating how patient responses to therapy differs depending on a tumor’s genetic makeup making biomarker testing a key element of the treatment decision-making process for these patients. However, significant gaps in molecular testing for biomarkers continue to exist and many patients either go untested, or don’t receive the appropriate targeted therapy even if they are tested. RAS family of genes are one of the most frequently mutated oncogenes driving some of the deadliest cancers including lung and CRC. As the industry is advancing the field to develop selective and effective anti-RAS therapeutics it has become increasingly important to consider upfront comprehensive biomarker testing, ahead of initial treatment, to understand the total genetic makeup of the tumor to optimize patient management.

In this session we will look at:

  • The importance of comprehensive biomarker testing for RAS driven cancers
  • The barriers to biomarker testing and strategies to overcome these hurdles
  • The current biomarker testing journey from a patient’s perspective.
  • Importance of the discussion between patient and clinician on how timely biomarker testing can guide a patient’s personalized treatment path
  • Role of patient groups, professional societies and clinical guideline committees to make BM testing for all a reality
Terri Conneran, KRAS Kickers

Terri Conneran
Founder & Advocate, Patient, Advocate & Founder
KRASKickers.org

Partha Das, Amgen

Partha Das
Medical Director & US Medical Affairs Lead, Oncology
Amgen

Lunch & Networking 2.00 | 11.00

Workshop E 3.00pm EDT I 12.00pm PDT

Peptide RAS Ligands: Mechanistic Insights & Recent Advances
Unmet need lies beyond reach of the agents currently under clinical investigation
for many patients with mutant RAS-driven cancers. Peptides present additional
opportunities to explore RAS protein dynamics, surface, and function. In this workshop, participants will interact with experts who identified peptidic RAS ligands and uncovered structural and/or mechanistic insights. This session will include a history of recently discovered peptide ligands to RAS, discuss a variety of approaches for identifying peptides with cellular function and lastly share structural and mechanistic insights from peptidic RAS ligands.

In this session we will look at:

  • What is an updated accounting of peptides that bind RAS?
  • What recent insights into RAS protein structure and function follow from peptide ligands?
  • What strategies can enable peptide ligands to achieve cellular and/or pharmacologic responses?
  • What opportunities and challenges face peptide ligands? Are they insightful mechanistic tools or potential clinical therapies?
Novartis

Andrei Golosov
Principal Scientist II
Novartis Institutes for BioMedical

Research

Lauren Monovich, Novartis

Lauren Monovich
Director
Novartis Institutes for BioMedical Research

Innovator of the Year:
Dehua Pei
Professor of Chemistry and Biochemistry
578 Bioscience Building Newman-Wolfram Laboratory
484 West 12th Ave.
pei.3@osu.edu
688-4068
 (Photo by Jodi Miller 614-580-0342)

Dehua Pei
Kimberly Professor
The Ohio State University

Workshop F 3.00pm EDT I 12.00pm PDT

Optimizing RAS Based Clinical Trials
As we shift gear toward deeper understanding of mechanisms of cancer progression and therapy resistance, it is essential that we consider the optimal requirements for clinical trial designs based on insights, learnings, and data to optimize results and accelerate development of novel anti-cancer agents. This session will delve into the evidence of clinical trials for anti-RAS targeted therapies and consider applications for future trials.

In this session we will look at:

  • Discuss successes in clinical trials and the benchmarks of optimized designs
  • Consider advantages & disadvantages of anti-RAS specific trial designs and requirements for patient diversity and inclusion
  • Leverage expert insights from various academic backgrounds
Vasmi NYU

Vamsidhar Velcheti
Associate Professor
Department of Medicine at NYU Grossman School of Medicine

petros-grivas

Petros Grivas
Associate Professor, Clinical Research Division
Fred Hutch

Mary Redman

Mary Redman
Professor, Clinical Research Division
Fred Hutch

End of Pre-conference Workshop Day 5.00pm EST I 2.00pm PST